Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ARGS $3.71 0.5673 +18.07%
CVM $0.49 0.0263 +5.70%
GALE $0.64 0.0123 +1.95%
CELG $99.75 1.8600 +1.90%
JUNO $26.94 0.4700 +1.78%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BCRX $1.82 -4.3200 -70.36%
CTIC $0.42 -0.6969 -62.22%
IMDZ $8.09 -1.9990 -19.81%
RXDX $7.89 -1.1200 -12.43%
CERU $2.03 -0.2599 -11.35%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

End-Of-Life Care Costs In US Comparable To Europe And Canada

(Forbes) Jan 19, 2016 - Published in JAMA, the report compares end-of-life care practices for patients dying with cancer in seven countries: Belgium, Canada, England, Germany, the Netherlands, Norway and the United States.
read article 



ASCO Official Participates in Vice President’s “Moonshot” Launch

(ASCO) Jan 15, 2016 - During Vice President Joe Biden’s formal launch today of his “moonshot” to cure cancer, the American Society of Clinical Oncology (ASCO) encouraged a comprehensive approach to accelerate the discovery of new cancer treatments, including issues related to enrollment in clinical trials, access to care, federal funding, and information technology and interoperability.
read press release 



The Best Missions for a Cancer Moonshot

(New York Times/Room for Debate) Jan 19, 2016 - Some cancer researchers say the idea of curing cancer with a massive government program relies on an outmoded, simplistic model of the disease.
read article 



VP Joe Biden Says Politics Are Impeding Cancer Cure

(CBS News/Associated Press) Jan 15, 2016 - Vice President Joe Biden launched a "moonshot" initiative Friday to hasten a cure for cancer, aiming to use his final year in office to break down barriers in the medical world he says are holding back progress on eradicating the dreaded disease.
read article 



MOLOGEN AG: First Combination Trial with MGN1703 and a Checkpoint Inhibitor in Collaboration with MD Anderson

(Yahoo! Finance) Jan 19, 2016 - The biotech company MOLOGEN AG today announced that it has entered into a collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson).
read article 



Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

(PipelineReview.com) Jan 19, 2016 - Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).
read article 



Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium

(Merck) Jan 19, 2016 - Seven registration-enabling trials evaluating Keytruda in patients with gastrointestinal cancers are planned or underway.
read corporate press release 



Pregabalin ‘Shouldn’t Be Prescribed As A Way To Control Bone Pain’

(EPM News) Jan 19, 2016 - A drug used to treat bone pain caused by cancer makes little difference to patients’ well-being, according to research by the University of Edinburgh.
read article 



Diabetes in Cancer Survivors a Late Effect of Abdominal Radiation?

(Medscape Medical News) Jan 19, 2016 - Children and young adults treated with total body or abdominal radiotherapy have an increased risk for insulin resistance and diabetes mellitus, but the exact underlying mechanisms remain unclear.
read article (free registration required) 



Who Is Caring for Cancer Survivors: Oncologists or PCPs?

(Medscape Medical News) Jan 18, 2016 - Is the ideal model of care for cancer survivors one led by oncologists, one led by primary care physicians (PCPs), or a shared model?
read article (free registration required) 



Fine-Tuned Test Predicts Risk Of Ovarian Cancer With Great Precision

(KU Leuven [Leuven, Belgium]) Jan 19, 2016 - In collaboration with scientists from Imperial College London and Lund University, Professors Dirk Timmerman and Ben Van Calster from KU Leuven have improved a test for ultrasound diagnosis of ovarian tumors.
read article 



Scientists Find New Gene Fault Behind Ovarian Cancer

(Cancer Research UK) Jan 19, 2016 - Women who carry an inherited fault in the gene BRIP1 are over three times more likely to develop ovarian cancer than those without the fault, according to a study published in the Journal of the National Cancer Institute.
read press release 



FDA Grants Priority Review Status To Eisai’s sNDA for Anticancer Drug Lenvatinib

(Pharmaceutical Business Review) Jan 19, 2016 - The US Food and Drug Administration (FDA) has granted priority review status to the supplemental new drug application (sNDA) submitted by Eisai for its anticancer agent lenvatinib mesylate to treat advanced or metastatic renal cell carcinoma.
read article 



Eisai's Lenvatinib Receives FDA Priority Review for the Potential Treatment of Advanced Renal Cell Carcinoma in Combination with Everolimus

(Eisai) Jan 17, 2016 - Supplemental application based on progression-free survival data from Study 205, a three-arm Phase 2 study comparing lenvatinib in combination with everolimus, everolimus alone and lenvatinib alone in these patients; Agency granted lenvatinib Breakthrough Therapy designation for investigational indication in July 2015.
read corporate press release 



New Targeted Hormone-Radiation Treatment Slows Growth of Midgut Neuroendocrine Tumors

(ASCO) Jan 15, 2016 - Early results from a phase III study of patients with previously treated, advanced midgut neuroendocrine tumors show that a novel therapy, 177Lutetium-DOTATATE (Lutathera), may substantially slow tumor growth.
read press release 



Everolimus Slows Growth of Neuroendocrine Tumors

(ASCO) Jan 15, 2016 - Researchers report the results of a new analysis from a phase III trial of patients with neuroendocrine tumors that begin in the gastrointestinal (GI) tract or have an unknown origin.
read press release 



New Regimen for Locally Advanced Rectal Cancer as Effective but Less Toxic Than Chemoradiation

(ASCO) Jan 15, 2016 - Findings from a Polish phase III study point to an additional treatment option for patients with advanced rectal cancer.
read press release 



Meaningful Use is Dead. Is It Time to Celebrate?

(KevinMD.com) Jan 14, 2016 - At the J.P. Morgan Healthcare Conference in San Francisco, Andrew Slavitt, acting administrator at the Centers for Medicare & Medicaid Services (CMS), announced on January 11 that "The Meaningful Use program as it has existed will now effectively be over, and replaced with something better" and later clarified on Twitter that "In 2016, MU as it has existed -- with MACRA -- will now be effectively over and replaced with something better."
read article 



MedPAC Recommends Cuts to 340B Drug Program

(MedPage Today) Jan 14, 2016 - An advisory body to Congress voted 14-3 in favor of a draft recommendation that would cut Part B drug payments rates for hospitals in the 340B Drug Pricing Program by 10%.
read article (free registration required) 



Botched French Drug Trial Leaves 1 Brain Dead, 5 in Hospital

(ABC News/Associated Press) Jan 15, 2016 - Six men were hospitalized — one of them brain-dead — after a drug trial in northwestern France, the country’s health minister said on Friday.
read article 



Sarepta Plunges on Harsh FDA Eteplirsen Review Ahead of Next Week's Advisory Panel Meeting

(TheStreet) Jan 15, 2016 - Sarepta Therapeutics' stock price plummeted Friday on a very negative clinical review of the company's Duchenne muscular dystrophy drug eteplirsen released by the U.S. Food and Drug Administration.
read article 



F.D.A. Faulted for Problems With Drug Tracking

(New York Times) Jan 14, 2016 - The system the Food and Drug Administration uses to keep data on drugs after they have come to market is incomplete, outdated and often inaccurate, federal investigators said.
read article 



Inaugural Symposium Highlights Notable Research in Survivorship Care

(ASCO) Jan 15, 2016 - Five studies exploring key issues affecting the care of cancer survivors will be presented at the 2016 Cancer Survivorship Symposium.
read press release 



OncoFusion Therapeutics Reacquires Rights to BET Bromodomain Inhibitors

(OncoFusion Therapeutics) Jan 15, 2016 - OncoFusion Therapeutics, Inc. announced today that it has reached an agreement with Medivation, Inc. to reacquire the rights to certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins identified and developed under a research and license agreement announced between the parties in April 2014.
read corporate press release 



Cancer Is Focus Of Deals At JPMorgan Conference

(CEN/The Biological SCENE) Jan 14, 2016 - Acquisitions and collaborations target immuno-oncology and other cancer-fighting techniques.
read article